Tracheobronchial Drug Exposure Should Not Be Confused with Parenchymal Target Achievement for Nebulized Amikacin - Top-Institutions - MDSpire

Tracheobronchial Drug Exposure Should Not Be Confused with Parenchymal Target Achievement for Nebulized Amikacin

  • By

  • Guofu Mao

  • Haizhen Lan

  • April 29, 2026

  • 0 min

Share

Top Institutions in Pulmonary

Brief introduction explaining scope and methodology.

  • #1

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Pulmonary Medicine
    • Infectious Diseases
    • Clinical Pharmacology

  • #2

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Pulmonary and Critical Care Medicine
    • Infectious Diseases
    • Pharmacology

  • #3

    Massachusetts General Hospital / Harvard Medical School
    Massachusetts General Hospital / Harvard Medical School

    Boston, MA

    Key Differentiators

    • Pulmonary Medicine
    • Critical Care
    • Pharmacology

  • #4

    University of Pittsburgh Medical Center (UPMC)
    University of Pittsburgh Medical Center (UPMC)

    Pittsburgh, PA

    Key Differentiators

    • Critical Care Medicine
    • Pulmonary Infectious Diseases
    • Pharmacology

Original Source(s)

Tracheobronchial Drug Exposure Should Not Be Confused with Parenchymal Target Achievement for Nebulized Amikacin

  • by Guofu Mao, Haizhen Lan

  • April 29, 2026

Related Content

Stewardship Cuts Steroid Prescribing

Behaviorally informed peer comparison feedback was associated with a gradual decline in glucocorticoid prescribing

Early Enteral Feeding Tied to Fewer Complications

Benefit driven by fewer infections and pulmonary events, though overall complication rates were similar

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.